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Increased C-Peptide Immunoreactivity in Insulin
Autoimmune Syndrome (Hirata Disease) Due to High
Molecular Weight Proinsulin
Richard G. Kay,a Peter Barker,b Keith Burling,b Mark Cohen,c David Halsall,d Frank Reimann,a,e
Fiona M. Gribble,a,e Robert K. Semple,f and David Churchd,*
BACKGROUND: Determination of C-peptide is important
in the investigation of unexplained hyperinsulinemic
hypoglycemia because a high C-peptide concentration
usually indicates endogenous insulin hypersecretion.
Insulin autoimmune syndrome (IAS) denotes hyperin-
sulinemic hypoglycemia due to insulin-binding antibod-
ies that prolong insulin half-life. C-peptide clearance is
considered to be unaffected, and although a marked
C-peptide immunoreactivity in hypoglycemic samples has
been reported, it has been suspected to be artifactual.
High-resolution mass spectrometry enables examination of
the basis of C-peptide-immunoreactivity in IAS.
METHODS: Precipitation of plasma with polyethylene gly-
col was followed by C-peptide immunoassay. Plasma pep-
tides extracted by solvent precipitation were characterized
by nano-LC–MS/MS and analyzed using an untargeted
data-dependent method. Peptides related to proinsulin, in
amino acid sequence, were identified using proprietary
bioinformatics software and confirmed by repeat LC–
MS/MS analysis. Gel filtration chromatography coupled
to LC–MS/MS was used to identify proinsulin-related
peptides present in IAS immunocomplexes. Results were
compared with those from C-peptide immunoassay.
RESULTS: Polyethylene glycol precipitation of IAS
plasma, but not control plasma, depleted C-peptide im-
munoreactivity consistent with immunoglobulin-bound
C-peptide immunoreactivity. LC–MS/MS detected pro-
insulin and des 31,32 proinsulin at higher abundance in
IAS plasma compared with control plasma. Analysis by
gel filtration chromatography coupled to LC–MS/MS
demonstrated proinsulin and des 31,32 proinsulin, but
no C-peptide, in plasma immunocomplexes.
CONCLUSIONS: Antibody binding can enrich proinsulin
and des 31,32 proinsulin in IAS immunocomplexes.
Proinsulin cross-reactivity in some C-peptide immuno-
assays can lead to artifactually increased C-peptide
results.
Introduction
Insulin autoimmune syndrome (IAS, or Hirata disease)
denotes spontaneous hyperinsulinemic hypoglycemia
due to insulin-binding autoantibodies in individuals not
receiving insulin therapy (1, 2). Autoantibodies form
immunocomplexes with insulin, sequestering acutely se-
creted insulin (3) and retarding its clearance (4), conse-
quently maintaining inappropriate total plasma insulin
concentrations compared with the contemporaneous
blood glucose concentration. Suspicion of the disorder
may arise following the finding of very high plasma in-
sulin concentration with an increased insulin/C-peptide
molar ratio in a hypoglycemic sample (5–7). Willful
misadministration of exogenous insulin is sometimes
confused with this profile and laboratory analysis
assumes decisive importance in discriminating these
entities.
Hyperinsulinemic hypoglycemia with high C-pep-
tide usually indicates endogenous insulin hypersecretion
(8). High C-peptide immunoreactivity has been
reported in IAS, even in the face of frequent profound
hypoglycemia (6, 7, 9–17). This has the potential to
confuse managing clinicians since normal endogenous
C-peptide production by the pancreas is inhibited in re-
sponse to exogenous insulin-induced hypoglycemia
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(18, 19). However, immunoassay of C-peptide may
yield artifactually increased results in IAS (7). The cause
of this is not known. The cause of putative interference
in C-peptide immunoassay is unconfirmed, although
cross-reactivity of antibody-bound proinsulin has been
postulated (10, 15); endoproteolytic cleavage of proin-
sulin and its intermediates des 64,65 proinsulin and des
31,32 proinsulin, generates (insulin and) C-peptide
(Fig. 1). The amino acid sequence of C-peptide, a single
polypeptide chain, is present in proinsulin, des 31,32
proinsulin, and des 64,65 proinsulin such that these
precursors have the potential to cross-react in C-peptide
immunoassay.
Identification of hormone immunocomplexes by
immunoassay is challenging because autoantibody and
assay reagents may compete to bind hormones, and the
signal generated in plasma is unlikely to represent solely
unbound or total (unbound plus bound) analyte.
Immunocomplexes can be separated by precipitation, or
by physical methods, such as gel filtration chromatogra-
phy (GFC) (5–7), to discriminate high molecular
weight (HMW, antibody-bound) and monomeric im-
munoreactivity. Mass spectrometry is an orthogonal
method to quantify plasma peptides that is not reliant
on immunoreactivity and exhibits far greater selectivity
than immunoassay. Until recently, mass spectrometry
has been limited by analytic sensitivity, but develop-
ments in both sensitivity and resolution of mass
spectrometers have greatly enhanced parallel analysis of
plasma peptides extracted from plasma by precipitation
(20), solid-phase extraction (SPE) (21), or targeted
extraction (22). Consequently, it is now possible to in-
terrogate the composition of antibody-bound peptide
complexes in IAS with far greater selectivity. Targeted
LC–MS/MS analysis offers highly specific quantification
of insulin and C-peptide (23, 24), while its untargeted
application in combination with bioinformatic analysis
can identify structurally similar peptides (20). In this
study, we analyzed IAS plasma using LC–MS/MS with
an untargeted peptidomic approach with the aim of
identifying whether C-peptide immunoreactivity was
attributable to cross-reacting proinsulin/proinsulin-
derived molecules.
Materials and Methods
PATIENTS AND BLOOD SAMPLING
Studies were performed in accordance with the
Declaration of Helsinki (2000). Heparinized plasma
samples from 7 patients with IAS were evaluated for po-
tential interference with a C-peptide immunoassay
by the UK Severe Insulin Resistance Supra-Regional
Assay Service, Cambridge University Hospitals NHS
Foundation Trust, Cambridge. A summary of the clini-
cal characteristics of patients studied, the investigations
undertaken on initial presentation, and the case histories
have been published (6, 7). Nonfasting blood samples
were collected on ice, and plasma separated and frozen
at 80 C until analysis. Insulin and C-peptide immu-
noreactivity in nonfasting neat plasma, and insulin im-
munoreactivity in the same sample following a 1 in 5
and a 1 in 50 dilution with assay diluent, were deter-
mined using the DiaSorin LIAISONVR XL.
PLASMA PRECIPITATION WITH POLYETHYLENE GLYCOL
Polyethylene glycol (PEG) precipitation studies were
performed as previously published (5), with PEG pre-
cipitation ratio (PPR) defined as the C-peptide immu-
noreactivity remaining in the supernatant following
PEG precipitation compared with that in matched
saline-diluted plasma, expressed as a percentage. To
overcome a LIAISON XL sampling error with PEG su-
pernatant (likely exacerbated by PEG-induced increased
viscosity), a 1 in 2 0.9% (w/v) saline dilution of PEG
supernatant was used.
UNTARGETED PLASMA PEPTIDOMIC ANALYSIS
Untargeted peptidomic analysis of separated heparinized
plasma, previously stored at 80 C before being
Fig. 1. Proinsulin processing. Mature insulin is cleaved
from proinsulin by the action of 3 peptidases: prohormone
convertase 1 (PC1), prohormone convertase 2 (PC2), and
carboxypeptidase H (CPH). The amino acid residues () are
cleaved by proteases with preferential processing of the
31/32 site before the 64/65 site. C-peptide and insulin (A
chain and B chain linked by 2 disulfide bonds) are secreted
in equimolar amounts with comparatively very low
amounts of the 2 des proinsulin forms being present in
the plasma of healthy individuals.
LC–MS Characterization of Proinsulin Derivatives in IAS
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thawed on ice, was undertaken. 50 mL were transferred
to an EppendorfVR microcentrifuge tube and protein pre-
cipitated with 300 mL 80% (v/v) aqueous acetonitrile
(ACN) solution before centrifugation at 12 000g for
10 min at 4 C. The resulting supernatant was removed
by aspiration and transferred to Eppendorf LoBind
microcentrifuge tubes. Using a BiotageVR SPE Dry sys-
tem, the solvent was evaporated under oxygen-free ni-
trogen heated to 40 C. Samples were reconstituted in
200 mL of 0.1% (v/v) formic acid (FA), and SPE was
performed using a Waters OasisVR PRiME HLB 96-well
mElution Plate as previously described (20). Eluate was
evaporated and the residue reconstituted in 75 mL of
10 mmol/L dithiothreitol in 50 mmol/L ammonium bi-
carbonate, then heated for 60 min at 60 C. 15 mL of
100 mmol/L iodoacetamide in 50 mmol/L ammonium
bicarbonate was then added, and the solution left in the
dark for 30 min before addition of 20 mL of 1% FA (v/
v). 30 mL samples were injected into the LC–MS system
(20). In brief, analysis employed a Thermo ScientificTM
UltiMateTM 3000 RSLC–nano system coupled to a
Thermo Scientific Q ExactiveTM Plus. Peptides were
captured on a 0.3 5 mm Thermo Scientific C18
PepMap100 peptide trap column for 15 min before
switching in-line to a 0.075 250 mm Thermo
Scientific EASY-SprayTM LC Column. Electrospray
analysis was carried out using a spray voltage of 1.8 kV,
and S-lens setting of 70 V. A full scan range of 400–
1600 m/z was used with a resolution of 75 000, before
the top 10 ions of each spectrum were selected for MS/
MS analysis. Ions selected for fragmentation were added
to an exclusion list for 30 s to prevent their repeated
fragmentation.
Data were compared with the human Swissprot
database (www.uniprot.org; downloaded 26-Oct-2017)
using Bioinformatics Solutions Inc. PEAKS Studio
v.8.5 (20). Mass spectra were matched against the data-
base with a “no enzyme” setting, with fixed cysteine car-
bamidomethylation, N-terminal acetylation, N-terminal
pyroglutamate, methionine oxidation, and C-terminal
amidation as variable modifications. Results were fil-
tered with a false positive discovery rate of 1% against a
decoy database, and at least one unique peptide match
was required. PEAKS software identified peptides of up
to 65 amino acids in length.
LC–MS/MS CHARACTERIZATION AND SEMIQUANTITATIVE
ANALYSIS OF INTACT PROINSULIN-DERIVED PEPTIDES
To identify intact plasma proteins composed of the pro-
insulin-derived peptides identified in the peptidomic
screen, plasma samples were reextracted and analyzed
without reduction and alkylation, keeping disulfide
bonds intact. 250 mL of plasma were transferred to a
2 mL 96-well plate, and 1 mL of aqueous 80% (v/v)
ACN with 1 ng/mL bovine insulin internal standard
was added then mixed for 20 s before centrifugation at
2900g for 10 min at 4 C. The supernatant was removed
and transferred to an Eppendorf LoBind plate and sol-
vent evaporated to dryness under oxygen-free nitrogen.
The residue was reconstituted in 200 mL 0.1% (v/v)
aqueous FA, and SPE was performed as described above.
Following elution, 75 mL 0.1% (v/v) FA was added to
reduce the organic solvent prior to direct LC–MS/MS
analysis.
Fifty microliters of sample extract were loaded at
300 mL/min onto a Waters ACQUITY UPLC HSS T3
Column (100 Å, 1.8 mm, 2.1 50 mm) heated to
60 C. Starting conditions were 78% A [0.1% FA in
water (v/v)) and 22% B (0.1% FA in ACN (v/v)],
changing to 68% A and 32% B after 6.4 min. The col-
umn was washed with 90% B for 1.6 min before return-
ing to the starting conditions for 2 min. MS was
performed in positive electrospray mode with a needle
voltage of 3 kV, gas flow settings of 55 and 10 for sheath
and aux, respectively. Temperatures were set at 350 C
for the gas aux, and 350 C for the transfer capillary,
and the S-lens was set at 70 V. MS data were acquired
from m/z 700–1600, with a resolution of 70 000 and an
automatic gain control target of 3 106 ions. LC–MS
data were interrogated for ions with m/z ratios assigned
to potential proinsulin-derived peptides.
To confirm ions attributed to putative proinsulin-
derived peptides, targeted product ion scan analysis of
extracts from an IAS plasma sample was performed. A
more proinsulin-centric LC–MS/MS analysis was used:
full scan analysis was performed from m/z 800–1600,
and a parallel-reaction monitoring-based analysis was
performed for proinsulin (m/z 1342.0), des 31,32 proin-
sulin (m/z 1300.0), des 31–33 proinsulin (m/z 1281.6),
insulin (m/z 1162.3), and C-peptide (m/z 1007.7). To
confirm identification of proinsulin, the WHO interna-
tional proinsulin standard (09/296) was obtained from
NIBSC and analyzed using LC–MS/MS. After the iden-
tities of proinsulin-derived peptides were established,
their relative abundances were assessed in IAS and con-
trol plasma.
GEL FILTRATION CHROMATOGRAPHY WITH C-PEPTIDE
IMMUNOASSAY OR LC–MS/MS
GFC of plasma from the same sample used above was
undertaken using a previously described protocol (5),
but adapted so that 3 mL fractions were collected [final
volume 3.5 mL, 4% (w/v) BSA]. Fractions were ana-
lyzed for C-peptide using the DiaSorin LIAISON XL
immunoassay.
GFC of plasma was then repeated on the same sam-
ple, with 3 mL fractions collected into 5 mL Eppendorf
LoBind microcentrifuge tubes following addition of
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10% (v/v) mouse plasma [5 mL, diluted in 0.1% (v/v)
FA]. HMW and monomeric fractions chosen for MS
analysis covered the GFC peaks demonstrable by
C-peptide immunoassay. Prior to SPE, 500 mL 6 mol/L
guanidine hydrochloride was added to each fraction to
release antibody-bound peptides. Eluent was diluted
with 75 mL 0.1% (v/v) FA, and 30mL of this solution
was analyzed by nano LC–MS/MS. A targeted parallel-
reaction monitoring-based analysis was again performed
for proinsulin (m/z 1342.0), des 31,32 proinsulin
(m/z 1300.0), des 31–33 proinsulin (m/z 1281.6), and
C-peptide (m/z 1007.7).
Results
Immunoassay results (Table 1) demonstrated marked
hyperinsulinemia in all patients, and dilution of plasma
revealed a high insulin/C-peptide molar ratio with an in-
crease in insulin immunoreactivity following correction
for dilution, characteristic of insulin-binding antibodies
(5–7).
PLASMA PRECIPITATION WITH POLYETHYLENE GLYCOL
To identify HMW C-peptide immunoreactivity, PEG
precipitation of 7 IAS plasma samples, and 8 control
plasma samples with C-peptide concentrations spanning
the DiaSorin LIAISON XL assay range, was undertaken
(Fig. 2). The median IAS PPR was 119%, lower than
the 156% median of control samples (Mann–Whitney
test, P¼ 0.0082).
NANO LC–MS/MS ANALYSIS OF REDUCED AND ALKYLATED
PLASMA EXTRACTS
To identify plasma peptides with primary structural
similarity to proinsulin, peptidomic analysis of the 6
IAS plasma samples with sufficient volume and 5 con-
trol plasma samples was undertaken. To detect both
antibody-bound and free peptides, ACN was added to
plasma to disrupt antibody–peptide interactions, and
the samples reduced and alkylated to break disulfide
bonds. Peptidomic analysis identified multiple peptides
matching proinsulin, including fully processed A and B
chains, and C-peptide. It also detected peptides span-
ning the B chain and C-peptide, and C-peptide and A
chain (Fig. 3). For one sample with an extremely high
concentration of antibody-bound insulin, 6 peptides
spanning the C-peptide and A chain cleavage site were
detected, in contrast to a single peptide spanning the
B chain and C-peptide cleavage site (Fig. 3, A). B chain-
C-peptide-cleavage site spanning peptides were not
found in any other samples, and in control subjects,
only fragments from fully processed prohormone were
Table 1. Insulin and C-peptide immunoreactivity in non-fasting plasma [adapted from Church et al. (6, 7)].
Patient number 1 2 3 4 5 6 7
Insulin (<60), pmol/L >3000 >3000 >3000 2906 2781 1340 782
Insulin (diluted 1 in 5), pmol/L >15 000 11 585 7020 5630 7805 3912 4601
Insulin (diluted 1 in 50), pmol/L 68 950 30 620 – 6605 12 100 5930 11 440
C-peptide (174–960), pmol/L 4960 5580 3750 3280 3110 1190 2380
Insulin/C-peptide (<1) – – – 0.9 0.9 1.1 0.3
Insulin (diluted 1 in 5)/C-peptide (<1) – 2.1 1.9 1.7 2.5 3.3 1.9
Insulin (diluted 1 in 50)/C-peptide (<1) 13.9 5.5 – 2.0 3.9 5.0 4.8
Insulin immunoreactivity was determined using the dilution factor following a 1 in 5 and a 1 in 50 dilution. Fasting reference limits are shown in brackets.
Fig. 2. Polyethylene glycol precipitation ratio (PPR, PEG su-
pernatant/saline, %) of C-peptide immunoreactivity of insu-
lin autoimmune syndrome (IAS) and control plasma. For
IAS, plasma median C-peptide PPR was 119% (interquartile
range 56–139%). For control plasma, median C-peptide
PPR was higher than IAS samples at 156% (149–171%)
(Mann–Whitney test, P¼ 0.0082). IAS plasma represented
as  was not used in mass spectrometry studies. IAS
plasma represented as  was used in gel filtration chroma-
tography studies.
LC–MS Characterization of Proinsulin Derivatives in IAS
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found (example shown in Fig. 3, B). The presence of
intact proinsulin could not be examined because the
bioinformatics software was limited to peptides of up to
65 amino acids in length.
LC–MS ANALYSIS OF INTACT PROINSULIN-DERIVED PEPTIDES
IN PLASMA
To identify intact disulfide-bonded peptide hormones
composed of the amino acid chains identified above
(proinsulin, split/des proinsulins, and insulin), 6 IAS
samples and 4 control samples were reextracted and ana-
lyzed, without reduction and alkylation, using high-
throughput analysis. The molecular weights of proinsu-
lin, des 31,32 proinsulin, and des 64,65 proinsulin were
assigned as 9382, 9090, and 9116, respectively, and the
theoretical m/z values of their [Mþ 5H]5þ to
[Mþ 9H]9þ charge states were calculated. Extracted ion
chromatograms were generated for these compounds
and, in addition to insulin and C-peptide, proinsulin
and des 31,32 proinsulin were identified (Supplemental
Fig. 1), but des 64,65 proinsulin was not detected.
Additional interrogation of the raw MS data of one IAS
plasma sample identified a peptide with a molecular
weight of 8964 Da, which eluted close to the des 31,32
proinsulin molecule, believed to be des 31–33
proinsulin (Supplemental Fig. 1, A). In contrast to IAS,
only peaks representing fully processed insulin and C-
peptide were detected in control plasma (Supplemental
Fig. 1, B).
LC–MS/MS CHARACTERIZATION OF INTACT PROINSULIN-
DERIVED PEPTIDES IN PLASMA EXTRACTS
To confirm the identity of the intact proinsulin/proin-
sulin-derived peptides, product ion spectra were gener-
ated and examined using high-throughput analysis.
Because proinsulin and des proinsulin forms contain
multiple disulfide bonds, their fragmentation patterns
could not be matched using the software and manual
matching was performed. Due to the large number of
fragmentation events that occurred in C-peptide, identi-
fication of product ion spectra for des 31,32 and des
31–33 was possible (Supplemental Fig. 2). Proinsulin,
in contrast, generated only a limited product ion spec-
trum containing multiple highly charged fragments
whose source was not ascertained (Supplemental Fig. 3,
A). Confirmatory matching was possible, however, fol-
lowing comparison of the product ion spectrum with a
proinsulin reference standard (Supplemental Fig. 3, B).
Des 31,32 and des 31–33 proinsulin standards could
not be obtained. Des 64,65 proinsulin was not included
Fig. 3. Plasma peptide matches to proinsulin in database search. Peptidomic analysis identified multiple peptides matching
proinsulin, including full-length A and B chains and C-peptide, in insulin autoimmune syndrome plasma (A). A number of pepti-
des spanning the B chain and C-peptide, and C-peptide and A chain, were detected, consistent with incomplete processing of
the proinsulin molecule. Intact proinsulin could not be identified because the software was limited to peptides of up to 65
amino acids in length. Analysis identified peptides matching A and B chains and C-peptide in control plasma (B).
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in this targeted analysis since the peptide had not been
detected in the characterization analysis using a full
scan.
SEMIQUANTITATIVE LC–MS/MS ANALYSIS OF PLASMA
EXTRACTS
Peptide peak area ratio values were generated by integrat-
ing the area under the curve using the Quan Browser
software (Thermo Fisher Scientific). Proinsulin/proinsu-
lin-derived peptide abundance was expressed as a ratio of
the peak area to the bovine insulin internal standard.
Unlike C-peptide, which appeared more abundant in
control than IAS plasma, proinsulin and des 31,32 proin-
sulin were present at higher concentrations in IAS than in
control plasma (Fig. 4). Des 31–33 proinsulin was
detected in one IAS plasma sample. As expected, insulin
was found to be more abundant in IAS than in control
plasma (data not shown).
IAS PLASMA ANALYSIS BY GEL FILTRATION
CHROMATOGRAPHY WITH C-PEPTIDE IMMUNOASSAY OR
LC–MS/MS
Analysis of GFC-separated IAS plasma fractions by
C-peptide immunoassay (Fig. 5), revealed 2 peaks: one
large peak of HMW C-peptide immunoreactivity, and
one much smaller peak consistent with monomeric
C-peptide immunoreactivity (Fig. 5, A). In contrast,
only monomeric C-peptide was demonstrated by
LC–MS/MS (Fig. 5, B), refuting the presence of
antibody-bound C-peptide in plasma. Small peaks of
HMW proinsulin and HMW des 31–33 proinsulin,
and a much larger peak of HMW des 31,32 proinsulin
were identified, however (Fig. 5, C). LC–MS/MS results
Fig. 4. Relative abundance of proinsulin-derived peptides
in insulin autoimmune syndrome (IAS). The mean (line)
and individual data points (peak area ratios compared with
bovine insulin internal standard) of proinsulin/proinsulin-
derived peptides from 6 IAS plasma samples compared
with 4 control samples. Data points below the limit of de-
tection of the assay are not shown. MS, mass spectrometry.
Fig. 5. Size separation of proinsulin-derived peptides.
Arrows show the elution volumes for immunoglobulin (Ig),
albumin (Alb), and monomeric C-peptide. Immunoassay
analysis demonstrated principally high molecular weight C-
peptide immunoreactivity (A). GFC–LC–MS/MS analysis of
the same plasma demonstrated only monomeric C-peptide
(B), and high molecular weight proinsulin, des 31,32 pro-
insulin, and des 31–33 proinsulin (C).
LC–MS Characterization of Proinsulin Derivatives in IAS
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were consistent with the presence of antibody-bound
proinsulin, des 31,32, and des 31-33 proinsulin in IAS
plasma in the sample analyzed. These 3 peptides contain
the C-peptide sequence, making cross-reactivity in the
C-peptide immunoassay feasible. In-house data indi-
cated proinsulin and insulin molar cross-reactivity of
120–140 and <0.01%, respectively, in the DiaSorin
LIAISON XL C-peptide immunoassay (data not
shown), consistent with the manufacturer’s and other
independent observations (25–27). HMW insulin was
demonstrated using immunoassay and LC–MS/MS,
consistent with insulin-antibody complexes present in
IAS (data not shown). GFC–C-peptide immunoassay
and GFC–LC–MS/MS were repeated on another IAS
plasma sample, and findings were broadly consistent
with those above; data demonstrated HMW C-peptide
immunoreactivity and MS HMW peaks for proinsulin,
des 31,32 proinsulin, but no C-peptide (or des 31–33
proinsulin) (data not shown).
Discussion
A disorder rarely reported in the West, IAS may be first
suspected in the context of spontaneous hypoglycemia
when a high insulin concentration and increased insu-
lin/C-peptide molar ratio is identified (7). This profile
may also occur in exogenous insulin administration
(28), although very high C-peptide immunoreactivity
will usually discriminate IAS from exogenous hyperinsu-
linemia. While suppression of C-peptide may be
expected in response to exogenous insulin administra-
tion, the presence of substantial C-peptide immunoreac-
tivity in the context of recurrent hypoglycemia in IAS
has not been explained.
IAS diagnosis requires confirmation of circulating
antiinsulin antibodies, but the presence of these is not
specific for IAS (7). Available antiinsulin–antibody
assays are, moreover, not standardized (29), and may be
neither sufficiently sensitive (7) nor specific (5). There is
thus clinical need to refine biochemical investigation of
IAS, and MS may be incorporated into investigative
algorithms as an orthogonal method that avoids the
analytic vulnerabilities of immunoassay in the context of
insulin autoimmunity.
C-peptide immunoassays can exhibit positive bias
relative to MS in IAS (7), but this has not been
explained. Suggested causes include antiinsulin–anti-
body complex interference (30), antibody binding to
C-peptide or C-peptide and proinsulin (31), and immu-
noassay cross-reactivity of proinsulin immunocomplexes
(10, 15). In one reported case of IAS, no endogenous-
antibody binding of C-peptide was found (15).
PEG precipitation of plasma can identify hormone-
immunoglobulin complexes, but is nonspecific and
assay-dependent (5). In our study here, proportionally
less C-peptide immunoreactivity remained following
PEG precipitation of IAS plasma, compared with con-
trol plasma. Together with the GFC results from this
study and from other reports (10, 15), this finding is
consistent with HMW C-peptide immunoreactivity in
IAS plasma, which is suggested to be an antibody-bound
immunoreactive species. There was some overlap
between IAS and control PPR values, and this may
be attributable to sample heterogeneity in IAS: more
monomeric C-peptide immunoreactivity, and/or less
antibody-bound immunoreactive species (either a lower
concentration or less immunoreactivity due to endoge-
nous-antibody binding), may result in a PPR value
closer to that of normal controls. It follows that use of
C-peptide PPR may have only limited sensitivity in the
investigation of suspected IAS, albeit a low PPR may be
used as corroborative evidence.
LC–MS/MS analysis after organic solvent disrup-
tion of peptide–antibody bonds, and precipitation of
large proteins (7), can establish total (unbound
plus bound) peptide concentrations without the bias
inherent in immunoassay. Using such a peptidomics
approach, we have now clarified the nature of the
immunocomplexes in IAS. No true C-peptide could be
identified by MS analysis in the antibody-bound frac-
tions. However, untargeted peptidomics detected multi-
ple peptides spanning the proinsulin A chain and
C-peptide, while targeted LC–MS/MS confirmed proin-
sulin and des 31,32 proinsulin at higher abundance in
IAS plasma than in control plasma. In only one IAS pa-
tient was des 31–33 proinsulin detected, and further
studies are required to determine whether this peptide is
synthesized in vivo or is an artifact produced ex vivo.
The higher proinsulin and des 31,32 proinsulin levels
detected in IAS plasma than in control plasma is consis-
tent with the prolonged half-life of these species, as well
as that of insulin itself, in IAS (4, 32). Although proin-
sulin is highly unlikely to interfere to a clinically signifi-
cant degree at normal proinsulin concentrations, it may
thus be abundant enough in IAS to explain aberrant im-
munoassay C-peptide results. Although the reduced and
alkylated peptide spanning the B chain and C-peptide
was detected, abundance of intact des 64, 65 proinsulin
in IAS plasma samples was insufficient to be detected
using MS. In contrast to 64,65 proinsulin, the peptides
proinsulin, des 31,32 proinsulin, and des 31–33 proin-
sulin, all have an intact link between the A chain and
C-peptide (Fig. 1); however, a comparative study of an-
tibody cross-reactivity using competitive radioligand
binding (33) was precluded by lack of suitable standards
for des proinsulin forms. Preferential processing of the
31/32 site before the 64/65 site has long been recog-
nized (34), and even though the involvement of prohor-
mone convertase 2 in the 64/65 processing has recently
been challenged (35), a faster cleavage at the 31/32 site
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would make production and thus detection of des 64/
65 insulin, which would be intact at the 31/32 site, less
likely.
Accurate quantification of all proinsulin forms that
have accumulated in plasma is required to determine
whether these peptides potentially contribute to dysgly-
cemia in IAS. C-peptide has not been shown to exhibit
marked insulin-like activity (36, 37), but intact proinsu-
lin (38), des 64,65 proinsulin, and des 31,32 proinsulin
(39, 40) all have glucose-lowering activity. Indeed, pro-
insulin-secreting neuroendocrine tumors (41, 42) caus-
ing hypoglycemia with insulin concentrations below
diagnostic thresholds (8) have been reported. It follows
that antibodies with specificity for proinsulin may give
rise to a subtype of IAS more challenging to discrimi-
nate. Further study of the kinetics/clearance of these
antibody-bound proinsulin-derived peptides may offer
further understanding of the pathophysiology of IAS.
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